Metabolic imprinting effects of specifically designed lipid component

US9532966B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9532966-B2
Application numberUS-201214126398-A
CountryUS
Kind codeB2
Filing dateJun 18, 2012
Priority dateJun 16, 2011
Publication dateJan 3, 2017
Grant dateJan 3, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to the use of specifically designed lipid component with optimal fatty acid profile, an enhanced portion of the palmitic acid residues in the sn-2 position and present as lipid globules with a phospholipid coating for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life.

First claim

Opening claim text (preview).

The invention claimed is: 1. A nutritional composition for improving body composition, the improvement of body composition being selected from the group consisting of increased lean body mass, decreased fat mass relative to total body weight, decreased visceral fat mass relative to total body weight, a decreased visceral fat mass relative to total fat mass, decreased fat accumulation and increased muscle mass, the composition comprising carbohydrates, protein and lipid, wherein the lipid is present in the form of lipid globules comprising: (a) linoleic acid and alpha-linolenic acid in a weight ratio of 2 to 10, (b) at least 10 wt. % palmitic acid based on total fatty acids, wherein at least 30 wt. % of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid, and (c) a surface at least partly coated with phospholipids, wherein the amount of phospholipids present in the nutritional composition being from 0.5 to 20 wt. % phospholipids based on total lipid, and wherein the nutritional composition is not human milk. 2. The nutritional composition according to claim 1 , comprising less than 15 wt.% linoleic acid and more than 1 wt.% alpha-linolenic acid based on total fatty acids. 3. The nutritional composition according to claim 1 , comprising at least 0.15 wt% n-3 LC-PUFA based on total fatty acids selected from the group consisting of DHA, EPA, and DPA. 4. The nutritional composition according to claim 1 , wherein at least 35 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid. 5. Then nutritional composition according to claim 1 , wherein the lipid globules have a volume mode diameter of 1.0 μm or above. 6. The nutritional composition according to claim 1 , comprising 0.5 to 20 wt.% phospholipids derived from mammalian milk based on total lipid. 7. The nutritional composition according to claim 1 , comprising a core of lipid globules comprising at least 40 wt.% of triglycerides of vegetable origin. 8. The nutritional composition according to claim 1 , comprising 10 to 50 wt.% lipids based on dry weight of the total composition. 9. The nutritional composition according to claim 1 , wherein the lipids provide 30 to 60% of the total calories, the protein provides 5 to 20% of the total calories and the digestible carbohydrates provide 25 to 75% of the total calories. 10. The nutritional composition according to claim 1 , wherein the protein provides 5 to 9% of the total calories. 11. The nutritional composition according to claim 1 , further comprising non digestible oligosaccharides. 12. The nutritional composition according to claim 1 , wherein the composition is a powder. 13. A method of prevention of obesity, reducing the risk of obesity, treatment of obesity, prevention of diabetes type 2, reducing the risk of occurrence of insulin resistance and improving insulin sensitivity, preventing metabolic syndrome, comprising administering to a subject in need thereof a composition according to claim 1 . 14. The method of claim 13 , wherein the nutritional composition is for feeding a human subject with an age between 0 and 36 months. 15. The method according to claim 14 , wherein the prevention, reduction, improvement is observed when the subject is over 36 months. 16. The method according to claim 13 , wherein the subject is a non-obese human subject. 17. The method according to claim 13 , wherein the composition is a preterm formula, infant formula, follow on formula or growing up milk. 18. A method of improving body composition, the improvement of body composition being selected from the group consisting of increased lean body mass, decreased fat mass relative to total body weight, decreased visceral fat mass relative to total body weight, a decreased visceral fat mass relative to total fat mass, decreased fat accumulation and increased muscle mass, the method comprising administering to a subject in need thereof a composition according to claim 1 . 19. A process for the manufacture of a nutritional composition according to claim 1 , comprising preparing an aqueous phase comprising protein and digestible carbohydrates and preparing a fat phase comprising lipids, wherein phospholipids are present in the aqueous and/or fat phase, wherein the fatty acid composition of the lipid comprises linoleic acid and alpha-linolenic acid in a weight ratio of 2 to 10, wherein the fatty acid composition of the lipid comprises at least 10 wt.% palmitic acid based on total fatty acids, and at least 30 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid, mixing the fat and aqueous phase and homogenizing the mixture of fat and aqueous phase into an oil-in-water emulsion with lipid globules at least partly coated on the surface with phospholipids, the amount of phospholipids present in the nutritional composition being from 0.5 to 20 wt.% phospholipids based on total lipid.

Assignees

Inventors

Classifications

  • for hyperglycaemia, e.g. antidiabetics · CPC title

  • Anorexiants; Antiobesity agents · CPC title

  • for osteoporosis · CPC title

  • Fatty acids or derivatives thereof · CPC title

  • A61K31/201Primary

    having one or two double bonds, e.g. oleic, linoleic acids · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9532966B2 cover?
The invention relates to the use of specifically designed lipid component with optimal fatty acid profile, an enhanced portion of the palmitic acid residues in the sn-2 position and present as lipid globules with a phospholipid coating for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life.
Who is the assignee on this patent?
Van Der Beek Eline Marleen, Abrahamse-Berkeveld Marieke, Oosting Annemarie, and 2 more
What technology area does this patent fall under?
Primary CPC classification A61K31/201. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).